Sort   by:  
 Page size 
MetabolomicsUntargeted LC-MS metabolomic studies of Asteraceae species to discover inhibitors of Leishmania major dihydroorotate dehydrogenase

INTRODUCTION: Interesting data about the family Asteraceae as a new source of Leishmania major dihydroorotate dehydrogenase (LmDHODH) inhibitors are presented. This key macromolecular target for parasites causing neglected diseases catalyzes the fourth reaction of the de novo pyr...

2019-10-14 | MTBLS722 | MetaboLights
TranscriptomicsTranscriptomic analysis by array of reactivation of dihydroorotate dehydrogenase by respiration restores tumor growth of mitochondrial DNA-depleted cancer cells.
Tumor cells without mitochondrial DNA (mtDNA) reconstitute oxidative phosphorylation (OXPHOS) by acquiring host mitochondria from stromal cells, but the reasons why functional respiration is crucial for tumorigenesis remain unclear. To address this issue, we used time-resolved analysis of the initia...
ORGANISM(S): Mus musculus 
2018-10-01 | E-MTAB-6150 | biostudies-arrayexpress
GenomicsDihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
PRJNA737115 | ENA
TranscriptomicsInhibition of dihydroorotate dehydrogenase by doxorubicin and brequinar sensitize cancer cells to TRAIL-induced apoptosis
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent in selectively killing tumor cells. However, TRAIL monotherapy is not especially successful due to the fact that many cancer cells are resistant to TRAIL. Chemotherapeutic agents, such as doxorubicin have been shown...
ORGANISM(S): Homo sapiens 
2013-06-01 | E-GEOD-42531 | biostudies-arrayexpress
MetabolomicsPlasmodium falciparum stable-isotope carbon labeling to explore metabolic consequences of keto–acid dehydrogenase disruption
Not available
ORGANISM(S): Plasmodium falciparum 
ST002024 | MetabolomicsWorkbench
GenomicsTargeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
PRJNA496503 | ENA
UnknownPharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.
Not available
S-EPMC6119157 | biostudies-literature
UnknownASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Not available
S-EPMC7556493 | biostudies-literature
UnknownPTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition.
Not available
S-EPMC5562025 | biostudies-literature
UnknownStructure of the putative dihydroorotate dehydrogenase from Streptococcus mutans.
Not available
S-EPMC3034605 | biostudies-literature
Sort   by:  
 Page size